Wegovy Faces Competition as Eli Lilly's Zepbound Shows Better Weight Loss Results in New Analysis

# Podcast Episode Description

## Title: Wegovy vs. Zepbound: Inside the High-Stakes Battle for Obesity Drug Dominance

**Episode Summary:**

The weight loss drug wars are heating up, and this week's episode breaks down everything happening in the fast-moving world of GLP-1 medications. From Eli Lilly's bold new claims that Zepbound outperforms Wegovy HD in head-to-head weight loss results, to Novo Nordisk's aggressive push into oral obesity medications, we unpack the data, the controversies, and what it all means for patients.

In this deep dive, we cover:

- **Zepbound vs. Wegovy HD**: Eli Lilly's September 29th analysis showing 20.2% average weight loss with Zepbound compared to 13.7% with Wegovy HD—and why the "indirect comparison" methodology matters - **The Wegovy Pill Boom**: How the oral semaglutide tablet hit 7 million U.S. prescriptions, with 90% paid in cash—and what that reveals about unmet patient demand - **Super Responders**: New real-world data suggesting patients who recently regained weight may see exceptional results with oral Wegovy - **Patent Cliff Ahead**: Why semaglutide's patent protection is expected to expire around 2031, and how Viatris/Mylan's Delaware lawsuit could reshape the generic drug timeline - **Novo's Pipeline Strategy**: Inside CagriSema, the company's next-generation combination therapy, and a new partnership with Nanexa for monthly or quarterly injectable formulations - **Beyond Weight Loss**: Singapore's approval of semaglutide for MASH (liver disease), expanding the drug's therapeutic footprint - **Safety and Legal Scrutiny**: Over 200 federal lawsuits alleging a link between GLP-1 drugs and NAION, a rare vision loss condition - **The Compounding Crackdown**: FDA warnings to Empower Pharmacy over semaglutide copies, and what it means for affordable access - **Words Matter**: Why Novo

Some great Deals https://amzn.to/49SJ3Qs

For more check out http://www.quietplease.ai